Lexeo Therapeutics, Inc.

NasdaqGM:LXEO Stock Report

Market Cap: US$398.9m

Lexeo Therapeutics Management

Management criteria checks 2/4

Lexeo Therapeutics' CEO is R. Townsend, appointed in Jan 2020, has a tenure of 6.33 years. total yearly compensation is $3.65M, comprised of 17.3% salary and 82.7% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $400.09K. The average tenure of the management team and the board of directors is 0.3 years and 3.5 years respectively.

Key information

R. Townsend

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage17.33%
CEO tenure6.3yrs
CEO ownership0.1%
Management average tenureless than a year
Board average tenure3.5yrs

Recent management updates

Recent updates

Seeking Alpha • Nov 06

Lexeo Therapeutics: Behind The Rebound

Summary Lexeo Therapeutics, Inc. has surged after FDA alignment on a pivotal trial for LX2006, targeting Friedreich’s ataxia cardiomyopathy. LX2006 shows promising efficacy and safety, with significant LVMI reduction and increased frataxin expression, positioning LXEO as a potential best-in-class therapy. LXEO is well-funded into 2028 after recent financings, and analysts remain bullish, forecasting strong revenue growth if LX2006 succeeds. Read the full article on Seeking Alpha
Analysis Article • Sep 25

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 20

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Oct 11

We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 16

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Summary Lexeo Therapeutics, Inc. achieved positive results across two studies using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy; Clinically meaningful improvements observed in several cardiac biomarkers. The global Friedreich's ataxia market is expected to reach $3.39 billion by 2034. Additional interim results, along with cardiac biopsy assessment in FA patients with LX2006, expected at an upcoming medical conference presentation in Fall of 2024. Interim results from two other programs expected in the 2nd half of 2024 are LX1001 for APOE4-associated Alzheimer's Disease and LX2020 for PKP2 arrhythmogenic cardiomyopathy. Read the full article on Seeking Alpha
Analysis Article • Jun 18

We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Apr 09

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Summary Lexeo Therapeutics, Inc. has results from its phase 1/2 SUNRISE-FA study, using LX-2006 for the treatment of patients with FA cardiomyopathy, expected in mid-2024. Results from all cohorts of phase 1/2 LEAD study, using LX-1001 for the treatment of patients with homozygous APOE4 AD, expected 2nd half of 2024. The global Alzheimer's Disease market is expected to reach $9.73 billion by 2030; It is said that between 15% to 25% of AD patients have this allele. Initiation of phase 1/2 HEROIC-PKP2 study, using LX-2020 for the treatment of patients with arrhythmogenic cardiomyopathy expected 1st half of 2024; Interim data to be released from cohort 1 in second half of 2024. Read the full article on Seeking Alpha
Seeking Alpha • Jan 29

Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's

Summary Lexeo is a small company developing gene therapies for Alzheimer's disease. LX1001 targets APOE4 homozygous patients with Alzheimer's disease by delivering a functional APOE2 gene using the AAVrh10 vector. Its other product, LX2006, targets FA cardiomyopathy using the same vector. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has R. Townsend's remuneration changed compared to Lexeo Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$88m

Dec 31 2025US$4mUS$633k

-US$100m

Sep 30 2025n/an/a

-US$105m

Jun 30 2025n/an/a

-US$114m

Mar 31 2025n/an/a

-US$109m

Dec 31 2024US$5mUS$600k

-US$98m

Sep 30 2024n/an/a

-US$87m

Jun 30 2024n/an/a

-US$77m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$2mUS$508k

-US$66m

Sep 30 2023n/an/a

-US$67m

Jun 30 2023n/an/a

-US$64m

Mar 31 2023n/an/a

-US$64m

Dec 31 2022US$705kUS$465k

-US$59m

Dec 31 2021US$3mUS$411k

-US$51m

Compensation vs Market: R.'s total compensation ($USD3.65M) is above average for companies of similar size in the US market ($USD2.60M).

Compensation vs Earnings: R.'s compensation has been consistent with company performance over the past year.

CEO

R. Townsend (44 yo)

6.3yrs
Tenure
US$3,650,940
Compensation

Mr. R. Nolan Townsend, MBA, is Director of Arbor Biotechnologies, Inc. from November 2023. He is Chief Executive Officer & Director of Lexeo Therapeutics, Inc since January 2020 Before joining Lexeo, Mr. T...

Leadership Team

NamePositionTenureCompensationOwnership
R. Townsend
CEO & Director6.3yrsUS$3.65m0.10%
$ 400.1k
Louis Tamayo
CFO & Principal Accounting Officerless than a yearUS$1.92mno data
Ronald Crystal
Co-Founderno datano datano data
Jose Otero
Chief Operating Officerless than a yearUS$3.56m0.035%
$ 138.1k
Eric Adler
Advisorless than a yearUS$3.16m0.018%
$ 70.0k
Narinder Bhalla
Chief Medical Officerless than a yearno datano data
Keith Wonnacott
Senior Vice President of Regulatory Affairsno datano datano data
Ryan McHenry
VP & Corporate Controller4.3yrsno datano data
0.3yrs
Average Tenure
48yo
Average Age

Experienced Management: LXEO's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
R. Townsend
CEO & Director6.3yrsUS$3.65m0.10%
$ 400.1k
Ronald Crystal
Co-Founder3.5yrsno datano data
Reinaldo Diaz
Independent Director4.3yrsUS$140.86k0%
$ 0
Mette Agger
Independent Director5.5yrsUS$140.86k0%
$ 0
Paula H. Cholmondeley
Independent Director4.5yrsUS$140.98k0.039%
$ 155.6k
Steven Altschuler Buser
Independent Chairman of the Board5.3yrsUS$163.36k0%
$ 0
Jeffery Molkentin
Member of Scientific Advisory Board3.5yrsno datano data
Eugene Yeo
Member of Scientific Advisory Board3.5yrsno datano data
Kiran Musunuru
Member of Scientific Advisory Board3.5yrsno datano data
Marianna Fontana
Member of Scientific Advisory Board3.5yrsno datano data
Iacopo Olivotto
Member of Scientific Advisory Board3.5yrsno datano data
Victoria Parikh
Member of Scientific Advisory Board3.5yrsno datano data
3.5yrs
Average Tenure
66yo
Average Age

Experienced Board: LXEO's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/29 23:32
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lexeo Therapeutics, Inc. is covered by 11 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Kristen KluskaCantor Fitzgerald & Co.
Yevgeniya LivshitsChardan Capital Markets, LLC